Use of AMH in the Differential Diagnosis of Anovulatory Disorders Including PCOS
- PMID: 33633686
- PMCID: PMC7901963
- DOI: 10.3389/fendo.2020.616766
Use of AMH in the Differential Diagnosis of Anovulatory Disorders Including PCOS
Abstract
Since the historical use of gonadotrophin and estradiol levels to define the different anovulatory disorders has shown some limitations, the use of other markers such as anti-müllerian hormone (AMH) has been proposed. This review addresses the role of AMH in the differential diagnosis of anovulatory disorders, especially focusing on its value in the prognostic characterization of their severity. Current limitations and future clinical applications are discussed.
Keywords: amenorrhea; anovulatory disorders; anti-Müllerian hormone; polycystic ovary syndrome; premature ovarian insufficiency.
Copyright © 2021 Capuzzo and La Marca.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
- Anovulatory infertility. The ESHRE Capri Workshop Group. Hum Reprod (1995) 10(6):1549–53. - PubMed
-
- Sacchi S, D’Ippolito G, Sena P, Marsella T, Tagliasacchi D, Maggi E, et al. The anti-Müllerian hormone (AMH) acts as a gatekeeper of ovarian steroidogenesis inhibiting the granulosa cell response to both FSH and LH. J Assist Reprod Genet (2016) 33(1):95–100. 10.1007/s10815-015-0615-y - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical